COLVERA®

Information for Patients

Be COLVERA® Certain

Every year there are approximately 140,000 newly diagnosed colorectal cancer cases in the United States. Following primary treatment, 30-50% of patients will experience a recurrence of their cancers, most of which will be within the first 2 – 3 years. (1)

Early detection of recurrent colorectal cancer may allow for additional treatment options and improved patient care.

COLVERA® detects twice the number of recurrent cases compared to CEA and can detect colorectal cancer recurrence up to 5 months earlier than CEA with a positive predictive value of 94%. (2, 3)

"Although the risk of recurrence varies by stage at time of diagnosis, more treatment options may be available when recurrence is detected early." (4)

Patients who have recently had surgery to remove colorectal cancer may wish to have the COLVERA® test to evaluate the presence or absence of residual disease.  Additional test results may help patients determine what is best for them and their family.

Additionally, patients currently being monitored for recurrence may wish to add COLVERA® to their protocol, as studies demonstrated COLVERA® detected twice as many recurrences as CEA. (2,3)

(2, 3) Early detection of recurrent colorectal cancer may allow for additional treatment options and improved patient care.

(4) National Cancer Institute 

Learn More About Long-Term Survival Care

How It Works

When cancer grows, tumors may shed DNA into the bloodstream.  This is called circulating tumor DNA (ctDNA). COLVERA® is a simple blood test that detects colorectal cancer ctDNA.

Testing with COLVERA®:

  • Two tubes of blood are drawn
  • Samples are sent to the Clinical Genomics laboratory
  • The blood is processed using state of the art technology to detect colorectal cancer ctDNA
  • Results are provided to physicians within 5-10 days

Answers To Common Questions

COLVERA® is a simple blood test that detects two methylated (silenced) colorectal cancer genes, BCAT1 and IKZF1, associated with colorectal tumor growth in circulating tumor DNA.

CEA measures the amount of a protein that may appear in the blood of a patient with colorectal cancer. Although CEA has been used for over three decades to monitor patients, the test is not positive in many patients with cancer and may yield false-positive results that can be caused by smoking and other non-cancer conditions.

CAN I GET TESTED WITH COLVERA®?
If your healthcare provider determines that COLVERA® is right for you, your provider can order the test. Your blood can be drawn in the physician’s office or at a Quest Diagnostics® Patient Service Center (PSC) near your provider’s office.

DO I NEED TO FAST BEFORE HAVING MY BLOOD DRAWN?
There is no need to change or modify your diet for testing.

WHAT IS THE SPECIMEN TYPE REQUIRED FOR TESTING?
COLVERA® only requires two 10 mL tubes of whole blood.  This is equivalent to about 1.5 tablespoons of blood.

HOW LONG DOES IT TAKE TO RECEIVE MY RESULTS?
Your healthcare provider will receive your test results from the Clinical Genomics Laboratory within 5-10 days.

HOW IS COLVERA® REPORTED?
COLVERA® results are reported as positive or not detected.

Clinical Genomics believes everyone should have access to the most innovative medical technology available, and we are committed to ensuring that COLVERA® is accessible and affordable. We accept all insurance plans and will bill on behalf of the patient. Also, Clinical Genomics has a Financial Assistance Program with multiple payment plans available based on the patient’s financial situation. We are dedicated to excellence and are here to assist with any questions or concerns patients and family members may have.​

References

(1) https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html

(2) Graeme P. Young, Susanne K. Pedersen, et al. A cross‐sectional study comparing a blood test for methylated BCAT1 and IKZF1 tumor‐derived DNA with CEA for detection of recurrent colorectal cancer. Cancer Medicine. 2016; 5 (10): 2763–2772.

(3) 69_symonds_et_al_2019a.pdf